Impact of Complete Response (CR) on Long-Term Survival Among Patients Receiving Axicabtagene Ciloleucel (axi-cel) for Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL)

Axi-cel is a CD19-directed autologous CAR T-cell therapy approved for the treatment of relapsed/refractory lymphomas. In a 5-year follow-up of ZUMA-1 (Neelapu et al, 2023) 58% of patients (pts) achieved CR, among whom 63% achieved CR by the week-4 assessment. Here, we evaluated the dynamics of achieving CR and its impact on survival in pts with R/R LBCL treated with axi-cel in the real world.Pts who received axi-cel for R/R LBCL in the US between 2017 –2020 after ≥ 2 lines of prior therapy and enrolled in the CIBMTR database were analyzed.

Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Armin Ghobadi, Theodora Anagnostou, Jacques Azzi, Mehdi Hamadani, Brent Logan, Michael T Hemmer, Sairah Ahmed, Sushma Bharadwaj, Alex F. Herrera, Caron A. Jacobson, Frederick L. Locke, Hai-Lin Wang, Myrna Nahas, Timothy Best, Sachin Vadgama, Zhen-Huan Hu, Tags: 248 Source Type: research